Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01082939 | Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | terminated | Phase 2 | 2 | University of FloridaOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT01532856 | Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years | unknown | Phase 3 | 64 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00116961 | Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | completed | Phase 2 | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00135187 | Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | completed | N/A | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 98 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00640523 | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 23, 2012 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00427765 | Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma | completed | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | completed | Phase 3 | 600 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma(VERTICAL) | completed | Phase 2 | 73 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 13, 2012 | clinicaltrials |
| NCT01175278 | Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures | withdrawn | N/A | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Jan 12, 2012 | clinicaltrials |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00505232 | Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)(LCM-04-02) | completed | Phase 2 | 30 | CABYCINDUSTRY | 1 | Jan 2, 2012 | clinicaltrials |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | withdrawn | Phase 2 | 0 | CABYCINDUSTRY | 1 | Dec 30, 2011 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00760370 | Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer | completed | Phase 2 | 60 | Vejle HospitalOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT00388999 | Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant | completed | Phase 1 | 46 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2011 | clinicaltrials |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | terminated | Phase 2 | 1 | The Christie NHS Foundation TrustOTHER | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma | completed | N/A | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT01478269 | Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen(ProDLBCL) | completed | — | 1,927 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Nov 23, 2011 | clinicaltrials |
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT01302912 | Lymphoma in the Orbit | unknown | — | 50 | University of ZurichOTHER | 1 | Nov 4, 2011 | clinicaltrials |
| NCT00478777 | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 150 | Celgene CorporationINDUSTRY | 1 | Nov 3, 2011 | clinicaltrials |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00281476 | The Effect of High Dose Simvastatine on Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Vejle HospitalOTHER | 0 | Nov 1, 2011 | clinicaltrials |
| NCT01459887 | Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | completed | Phase 3 | 278 | Shanghai CP Guojian Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 26, 2011 | clinicaltrials |
| NCT00036257 | Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 15 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00073489 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00907348 | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma(REAL07) | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | unknown | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 222 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Oct 10, 2011 | clinicaltrials |
| NCT00530140 | Idiotypic Vaccination for Follicular Lymphoma Patients(FLIDVAX2006) | unknown | Phase 2 | 100 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 6, 2011 | clinicaltrials |
| NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | completed | Phase 1 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 28, 2011 | clinicaltrials |
| NCT01042717 | Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | unknown | N/A | 10 | Shi, Patricia, M.D.INDIV | 1 | Sep 27, 2011 | clinicaltrials |
| NCT01114048 | Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)(KMM-97) | unknown | Phase 2 | 78 | Chonnam National University HospitalOTHER | 1 | Sep 22, 2011 | clinicaltrials |
| NCT01328236 | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia(Bortezomib) | unknown | Phase 2 | 20 | Clinical Service, ChinaINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT00712062 | Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | Sep 20, 2011 | clinicaltrials |
| NCT00443235 | GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | completed | Phase 3 | 260 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00652041 | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma(TaCyDexVMP7) | completed | Phase 4 | 40 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00504634 | Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2011 | clinicaltrials |
| NCT00934986 | Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia(LLC-NK) | completed | N/A | 70 | Institut Paoli-CalmettesOTHER | 1 | Sep 14, 2011 | clinicaltrials |
| NCT01221103 | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | unknown | Phase 1 / Phase 2 | 50 | Southern Europe New Drug OrganizationOTHER | 1 | Sep 13, 2011 | clinicaltrials |
| NCT00113932 | UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma | completed | Phase 2 | 140 | University of ArkansasOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00118339 | Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma | completed | N/A | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 1, 2011 | clinicaltrials |
| NCT01051115 | Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease(D'ACCORD) | unknown | Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 31, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2012source: clinicaltrials